{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:29:49Z","timestamp":1794277789476,"version":"4.9.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41575-020-0300-1","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T07:02:46Z","timestamp":1589180566000},"page":"487-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":926,"title":["Pancreatic cancer stroma: an update on therapeutic targeting strategies"],"prefix":"10.1038","volume":"17","author":[{"given":"Abdel N.","family":"Hosein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2377","authenticated-orcid":false,"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"300_CR1","unstructured":"American Cancer Society. Facts and Figures (American Cancer Society, 2019)."},{"key":"300_CR2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"300_CR3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","volume":"363","author":"D Li","year":"2004","unstructured":"Li, D. et al. Pancreatic cancer. Lancet 363, 1049\u20131057 (2004).","journal-title":"Lancet"},{"key":"300_CR4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"300_CR5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"300_CR6","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"300_CR7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"300_CR8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731\u2013739 (2018).","journal-title":"N. Engl. J. Med."},{"key":"300_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"300_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"300_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203 (2017).","journal-title":"Cancer Cell"},{"key":"300_CR12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"E Collisson","year":"2011","unstructured":"Collisson, E. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"300_CR13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u201378 (2015).","journal-title":"Nat. Genet."},{"key":"300_CR14","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/j.celrep.2017.11.003","volume":"21","author":"R Nicolle","year":"2017","unstructured":"Nicolle, R. et al. Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts. Cell Rep. 21, 2458\u20132470 (2017).","journal-title":"Cell Rep."},{"key":"300_CR15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999\u20132013 (2018).","journal-title":"Gastroenterology"},{"key":"300_CR16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006676-200411000-00003","volume":"29","author":"CE Binkley","year":"2004","unstructured":"Binkley, C. E. et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 29, 254\u2013263 (2004).","journal-title":"Pancreas"},{"key":"300_CR17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2004.12.036","volume":"128","author":"MG Bachem","year":"2005","unstructured":"Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907\u2013921 (2005).","journal-title":"Gastroenterology"},{"key":"300_CR18","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1158\/1078-0432.CCR-03-0825","volume":"10","author":"T Armstrong","year":"2004","unstructured":"Armstrong, T. et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10, 7427\u20137437 (2004).","journal-title":"Clin. Cancer Res."},{"key":"300_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00006676-200410000-00002","volume":"29","author":"MV Apte","year":"2004","unstructured":"Apte, M. V. et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179\u2013187 (2004).","journal-title":"Pancreas"},{"key":"300_CR20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786\u2013801 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"300_CR21","first-page":"1321","volume":"48","author":"S Linder","year":"2001","unstructured":"Linder, S. et al. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology 48, 1321\u20131327 (2001).","journal-title":"Hepatogastroenterology"},{"key":"300_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bjc.6605107","volume":"101","author":"D Ohlund","year":"2009","unstructured":"Ohlund, D. et al. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br. J. Cancer 101, 91\u201397 (2009).","journal-title":"Br. J. Cancer"},{"key":"300_CR23","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott, C. J. et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561\u20133568 (2015).","journal-title":"Clin. Cancer Res."},{"key":"300_CR24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/1078-0432.CCR-15-1615","volume":"23","author":"Y Zhong","year":"2017","unstructured":"Zhong, Y. et al. Mutant p53 together with TGFbeta signaling influence organ-specific hematogenous colonization patterns of pancreatic cancer. Clin. Cancer Res. 23, 1607\u20131620 (2017).","journal-title":"Clin. Cancer Res."},{"key":"300_CR25","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-154","volume":"13","author":"D Ohlund","year":"2013","unstructured":"Ohlund, D. et al. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 13, 154 (2013).","journal-title":"BMC Cancer"},{"key":"300_CR26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4082","volume":"22","author":"H Laklai","year":"2016","unstructured":"Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497\u2013505 (2016).","journal-title":"Nat. Med."},{"key":"300_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9\u201322 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"300_CR28","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/ijc.25942","volume":"129","author":"JJ Grzesiak","year":"2011","unstructured":"Grzesiak, J. J. et al. Knockdown of the beta1 integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int. J. Cancer 129, 2905\u20132915 (2011).","journal-title":"Int. J. Cancer"},{"key":"300_CR29","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1053\/j.gastro.2015.07.058","volume":"149","author":"NS Nagathihalli","year":"2015","unstructured":"Nagathihalli, N. S. et al. Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer. Gastroenterology 149, 1932\u20131943 (2015).","journal-title":"Gastroenterology"},{"key":"300_CR30","doi-asserted-by":"crossref","first-page":"8668","DOI":"10.1021\/acsnano.7b01026","volume":"11","author":"T Ji","year":"2017","unstructured":"Ji, T. et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy. ACS Nano 11, 8668\u20138678 (2017).","journal-title":"ACS Nano"},{"key":"300_CR31","first-page":"367","volume":"291","author":"SN Iyer","year":"1999","unstructured":"Iyer, S. N., Gurujeyalakshmi, G. & Giri, S. N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367\u2013373 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"300_CR32","first-page":"211","volume":"289","author":"SN Iyer","year":"1999","unstructured":"Iyer, S. N., Gurujeyalakshmi, G. & Giri, S. N. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 289, 211\u2013218 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"300_CR33","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong, B. et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909\u20132914 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1020\u20131027 (2019).","journal-title":"JAMA Oncol."},{"key":"300_CR35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","journal-title":"Cancer Cell"},{"key":"300_CR36","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","volume":"9","author":"CB Thompson","year":"2010","unstructured":"Thompson, C. B. et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9, 3052\u20133064 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"300_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112\u2013120 (2013).","journal-title":"Gut"},{"key":"300_CR38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ccr.2014.06.003","volume":"26","author":"VP Chauhan","year":"2014","unstructured":"Chauhan, V. P. et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26, 14\u201315 (2014).","journal-title":"Cancer Cell"},{"key":"300_CR39","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bpj.2016.03.040","volume":"110","author":"CC DuFort","year":"2016","unstructured":"DuFort, C. C. et al. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys. J. 110, 2106\u20132119 (2016).","journal-title":"Biophys. J."},{"key":"300_CR40","doi-asserted-by":"crossref","first-page":"L10","DOI":"10.1016\/j.bpj.2012.05.028","volume":"103","author":"J Hunger","year":"2012","unstructured":"Hunger, J. et al. Hydration dynamics of hyaluronan and dextran. Biophys. J. 103, L10\u2013L12 (2012).","journal-title":"Biophys. J."},{"key":"300_CR41","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","volume":"37","author":"RK Ramanathan","year":"2019","unstructured":"Ramanathan, R. K. et al. Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 37, 1062\u20131069 (2019).","journal-title":"J. Clin. Oncol."},{"key":"300_CR42","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02715804 (2019)."},{"issue":"Suppl. 4","key":"300_CR43","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.2020.38.4_suppl.638","volume":"38","author":"M Tempero","year":"2020","unstructured":"Tempero, M. et al. HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel\/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). J. Clin. Oncol. 38 (Suppl. 4), 638 (2020).","journal-title":"J. Clin. Oncol."},{"key":"300_CR44","unstructured":"Halozyme Therapeutics. Halozyme announces HALO-301 phase 3 study fails to meet primary endpoint Halozyme.com https:\/\/www.halozyme.com\/investors\/news-releases\/news-release-details\/2019\/Halozyme-Announces-HALO-301-Phase-3-Study-Fails-To-Meet-Primary-Endpoint\/default.aspx (2019)."},{"key":"300_CR45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","volume":"75","author":"JJ Kamphorst","year":"2015","unstructured":"Kamphorst, J. J. et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544\u2013553 (2015).","journal-title":"Cancer Res."},{"key":"300_CR46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm.4256","volume":"23","author":"SM Davidson","year":"2017","unstructured":"Davidson, S. M. et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat. Med. 23, 235\u2013241 (2017).","journal-title":"Nat. Med."},{"key":"300_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16031","volume":"8","author":"O Olivares","year":"2017","unstructured":"Olivares, O. et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat. Commun. 8, 16031 (2017).","journal-title":"Nat. Commun."},{"issue":"Suppl.","key":"300_CR48","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1538-7445.AM2017-1489","volume":"77","author":"GK Scott","year":"2017","unstructured":"Scott, G. K. et al. Targeting the mitochondrial enzyme proline dehydrogenase with a mechanism-based irreversible inhibitor induces selective mitochondrial stress and enhances breast cancer cell death under hypoxia [abstract]. Cancer Res. 77 (Suppl.), 1489 (2017).","journal-title":"Cancer Res."},{"key":"300_CR49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/embor.2012.127","volume":"13","author":"N Rath","year":"2012","unstructured":"Rath, N. & Olson, M. F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13, 900\u2013908 (2012).","journal-title":"EMBO Rep."},{"key":"300_CR50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.15252\/emmm.201606743","volume":"9","author":"N Rath","year":"2017","unstructured":"Rath, N. et al. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol. Med. 9, 198\u2013218 (2017).","journal-title":"EMBO Mol. Med."},{"key":"300_CR51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8504","volume":"9","author":"C Vennin","year":"2017","unstructured":"Vennin, C. et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci. Transl. Med. 9, eaai8504 (2017).","journal-title":"Sci. Transl. Med."},{"key":"300_CR52","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","volume":"10","author":"JB Stokes","year":"2011","unstructured":"Stokes, J. B. et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 10, 2135\u20132145 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"300_CR53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851\u2013860 (2016).","journal-title":"Nat. Med."},{"key":"300_CR54","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02546531 (2019)."},{"issue":"Suppl. 4)","key":"300_CR55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2018.36.4_suppl.380","volume":"36","author":"ALA Wang-Gillam","year":"2018","unstructured":"Wang-Gillam, A. L. A. et al. Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. J. Clin. Oncol. 36 (Suppl. 4), 380 (2018).","journal-title":"J. Clin. Oncol."},{"key":"300_CR56","doi-asserted-by":"crossref","first-page":"11745","DOI":"10.1158\/0008-5472.CAN-06-2322","volume":"66","author":"Y Shintani","year":"2006","unstructured":"Shintani, Y. et al. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 66, 11745\u201311753 (2006).","journal-title":"Cancer Res."},{"key":"300_CR57","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1083\/jcb.200708137","volume":"180","author":"Y Shintani","year":"2008","unstructured":"Shintani, Y. et al. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol. 180, 1277\u20131289 (2008).","journal-title":"J. Cell Biol."},{"key":"300_CR58","doi-asserted-by":"crossref","first-page":"23208","DOI":"10.1074\/jbc.M116.740605","volume":"291","author":"H Huang","year":"2016","unstructured":"Huang, H. et al. Up-regulation of N-cadherin by collagen I-activated discoidin domain receptor 1 in pancreatic cancer requires the adaptor molecule Shc1. J. Biol. Chem. 291, 23208\u201323223 (2016).","journal-title":"J. Biol. Chem."},{"key":"300_CR59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"300_CR60","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/nature22963","volume":"547","author":"NM Aiello","year":"2017","unstructured":"Aiello, N. M. et al. Upholding a role for EMT in pancreatic cancer metastasis. Nature 547, E7\u2013E8 (2017).","journal-title":"Nature"},{"key":"300_CR61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.devcel.2018.05.027","volume":"45","author":"NM Aiello","year":"2018","unstructured":"Aiello, N. M. et al. EMT subtype influences epithelial plasticity and mode of cell migration. Dev. Cell 45, 681\u2013695 (2018).","journal-title":"Dev. Cell"},{"key":"300_CR62","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1535-7163.MCT-16-0834","volume":"16","author":"KY Aguilera","year":"2017","unstructured":"Aguilera, K. Y. et al. Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 16, 2473\u20132485 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"300_CR63","volume":"17","author":"H Hur","year":"2017","unstructured":"Hur, H. et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. BMC Cancer 17, 87 (2017).","journal-title":"BMC Cancer"},{"key":"300_CR64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.4041","volume":"22","author":"C Ambrogio","year":"2016","unstructured":"Ambrogio, C. et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat. Med. 22, 270\u2013277 (2016).","journal-title":"Nat. Med."},{"key":"300_CR65","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"300_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/scientificamerican1098-33","volume":"279","author":"C Ezzell","year":"1998","unstructured":"Ezzell, C. Starving tumors of their lifeblood. Sci. Am. 279, 33\u201334 (1998).","journal-title":"Sci. Am."},{"key":"300_CR67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug. Discov. 3, 391\u2013400 (2004).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"300_CR68","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.pan.2016.05.393","volume":"16","author":"F Di Maggio","year":"2016","unstructured":"Di Maggio, F. et al. Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma. Pancreatology 16, 995\u20131004 (2016).","journal-title":"Pancreatology"},{"key":"300_CR69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MPA.0000000000000499","volume":"45","author":"T Nishida","year":"2016","unstructured":"Nishida, T. et al. Low stromal area and high stromal microvessel density predict poor prognosis in pancreatic cancer. Pancreas 45, 593\u2013600 (2016).","journal-title":"Pancreas"},{"key":"300_CR70","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/sj.bjc.6690248","volume":"79","author":"N Ikeda","year":"1999","unstructured":"Ikeda, N. et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 79, 1553\u20131563 (1999).","journal-title":"Br. J. Cancer"},{"key":"300_CR71","first-page":"1309","volume":"3","author":"J Itakura","year":"1997","unstructured":"Itakura, J. et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3, 1309\u20131316 (1997).","journal-title":"Clin. Cancer Res."},{"key":"300_CR72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00006676-200301000-00010","volume":"26","author":"P Buchler","year":"2003","unstructured":"Buchler, P. et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26, 56\u201364 (2003).","journal-title":"Pancreas"},{"key":"300_CR73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.onc.1206122","volume":"22","author":"D Wei","year":"2003","unstructured":"Wei, D. et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319\u2013329 (2003).","journal-title":"Oncogene"},{"key":"300_CR74","first-page":"4721","volume":"23","author":"T Shibaji","year":"2003","unstructured":"Shibaji, T. et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23, 4721\u20134727 (2003).","journal-title":"Anticancer Res."},{"key":"300_CR75","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ijc.1202","volume":"92","author":"J Luo","year":"2001","unstructured":"Luo, J. et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int. J. Cancer 92, 361\u2013369 (2001).","journal-title":"Int. J. Cancer"},{"key":"300_CR76","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1158\/1078-0432.CCR-03-0820","volume":"10","author":"M Fukasawa","year":"2004","unstructured":"Fukasawa, M. & Korc, M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 10, 3327\u20133332 (2004).","journal-title":"Clin. Cancer Res."},{"key":"300_CR77","first-page":"4221","volume":"9","author":"M Bockhorn","year":"2003","unstructured":"Bockhorn, M. et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin. Cancer Res. 9, 4221\u20134226 (2003).","journal-title":"Clin. Cancer Res."},{"key":"300_CR78","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","volume":"23","author":"HL Kindler","year":"2005","unstructured":"Kindler, H. L. et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033\u20138040 (2005).","journal-title":"J. Clin. Oncol."},{"key":"300_CR79","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","volume":"28","author":"HL Kindler","year":"2010","unstructured":"Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617\u20133622 (2010).","journal-title":"J. Clin. Oncol."},{"key":"300_CR80","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231\u20132237 (2009).","journal-title":"J. Clin. Oncol."},{"key":"300_CR81","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","volume":"49","author":"P Rougier","year":"2013","unstructured":"Rougier, P. et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur. J. Cancer 49, 2633\u20132642 (2013).","journal-title":"Eur. J. Cancer"},{"key":"300_CR82","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe, D. D. et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14, 7272\u20137283 (2008).","journal-title":"Clin. Cancer Res."},{"key":"300_CR83","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","volume":"12","author":"HL Kindler","year":"2011","unstructured":"Kindler, H. L. et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256\u201362 (2011).","journal-title":"Lancet Oncol."},{"key":"300_CR84","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099\u20137109 (2004).","journal-title":"Cancer Res."},{"key":"300_CR85","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","volume":"23","author":"A Goncalves","year":"2012","unstructured":"Goncalves, A. et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol. 23, 2799\u2013805 (2012).","journal-title":"Ann. Oncol."},{"key":"300_CR86","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4161\/cbt.23625","volume":"14","author":"JR Infante","year":"2013","unstructured":"Infante, J. R. et al. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biol. Ther. 14, 340\u2013346 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"300_CR87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"S Pennacchietti","year":"2003","unstructured":"Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347\u2013361 (2003).","journal-title":"Cancer Cell"},{"key":"300_CR88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232\u2013239 (2009).","journal-title":"Cancer Cell"},{"key":"300_CR89","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231 (2009).","journal-title":"Cancer Cell"},{"key":"300_CR90","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1073\/pnas.1018866109","volume":"109","author":"SJ Conley","year":"2012","unstructured":"Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad. Sci. USA 109, 2784\u20132789 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR91","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-11-1185","volume":"17","author":"C Carbone","year":"2011","unstructured":"Carbone, C. et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin. Cancer Res. 17, 5822\u20135832 (2011).","journal-title":"Clin. Cancer Res."},{"key":"300_CR92","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/0008-5472.CAN-13-2800","volume":"74","author":"KY Aguilera","year":"2014","unstructured":"Aguilera, K. Y. et al. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res. 74, 1032\u20131044 (2014).","journal-title":"Cancer Res."},{"key":"300_CR93","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987\u2013989 (2001).","journal-title":"Nat. Med."},{"key":"300_CR94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362 (2005).","journal-title":"Science"},{"key":"300_CR95","doi-asserted-by":"crossref","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel, S., Wong, A. H. & Jain, R. K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med. 2, a006486 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"300_CR96","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI36579","volume":"119","author":"M Galluzzo","year":"2009","unstructured":"Galluzzo, M. et al. Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J. Clin. Invest. 119, 865\u201375 (2009).","journal-title":"J. Clin. Invest."},{"key":"300_CR97","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature01784","volume":"424","author":"G Serini","year":"2003","unstructured":"Serini, G. et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 391\u2013397 (2003).","journal-title":"Nature"},{"key":"300_CR98","first-page":"3356","volume":"119","author":"F Maione","year":"2009","unstructured":"Maione, F. et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 119, 3356\u20133372 (2009).","journal-title":"J. Clin. Invest."},{"key":"300_CR99","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","volume":"24","author":"A Casazza","year":"2013","unstructured":"Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695\u2013709 (2013).","journal-title":"Cancer Cell"},{"key":"300_CR100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4807","volume":"10","author":"N Gioelli","year":"2018","unstructured":"Gioelli, N. et al. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci. Transl. Med. 10, eaah4807 (2018)","journal-title":"Sci. Transl. Med."},{"key":"300_CR101","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1158\/0008-5472.CAN-16-0300","volume":"76","author":"ME Gilles","year":"2016","unstructured":"Gilles, M. E. et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 76, 7181\u20137193 (2016).","journal-title":"Cancer Res."},{"key":"300_CR102","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395\u20132406 (2018).","journal-title":"N. Engl. J. Med."},{"key":"300_CR103","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","volume":"4","author":"JE Murphy","year":"2018","unstructured":"Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 4, 963\u2013969 (2018).","journal-title":"JAMA Oncol."},{"key":"300_CR104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum, I. B. et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665\u2013674 (2014).","journal-title":"Cancer Res."},{"key":"300_CR105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3389\/fimmu.2017.01097","volume":"8","author":"F Raggi","year":"2017","unstructured":"Raggi, F. et al. Regulation of human macrophage M1-M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1. Front. Immunol. 8, 1097 (2017).","journal-title":"Front. Immunol."},{"key":"300_CR106","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR107","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu, D. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front. Immunol. 9, 1878 (2018).","journal-title":"Front. Immunol."},{"key":"300_CR108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007669","volume":"4","author":"CL Roland","year":"2009","unstructured":"Roland, C. L. et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 4, e7669 (2009).","journal-title":"PLoS One"},{"key":"300_CR109","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878\u20134886 (2003).","journal-title":"Blood"},{"key":"300_CR110","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"300_CR111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","volume":"88","author":"AW Griffioen","year":"1996","unstructured":"Griffioen, A. W. et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88, 667\u2013673 (1996).","journal-title":"Blood"},{"key":"300_CR112","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171\u20136180 (2010).","journal-title":"Cancer Res."},{"key":"300_CR113","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian, L. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250\u2013254 (2017).","journal-title":"Nature"},{"key":"300_CR114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1541-7786.MCR-18-0427","volume":"17","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer. Mol. Cancer Res. 17, 348\u2013355 (2019).","journal-title":"Mol. Cancer Res."},{"key":"300_CR115","volume":"2","author":"JL Rinn","year":"2006","unstructured":"Rinn, J. L. et al. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet. 2, e119 (2006).","journal-title":"PLoS Genet."},{"key":"300_CR116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI93555","volume":"128","author":"MD Lynch","year":"2018","unstructured":"Lynch, M. D. & Watt, F. M. Fibroblast heterogeneity: implications for human disease. J. Clin. Invest. 128, 26\u201335 (2018).","journal-title":"J. Clin. Invest."},{"key":"300_CR117","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"300_CR118","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918\u2013926 (2008).","journal-title":"Cancer Res."},{"key":"300_CR119","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"300_CR120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735\u2013747 (2014).","journal-title":"Cancer Cell"},{"key":"300_CR121","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"300_CR122","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI30082","volume":"117","author":"MB Omary","year":"2007","unstructured":"Omary, M. B. et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117, 50\u201359 (2007).","journal-title":"J. Clin. Invest."},{"key":"300_CR123","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-18-1955","volume":"25","author":"V Bernard","year":"2018","unstructured":"Bernard, V. et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin. Cancer Res. 25, 2194\u20132205 (2018).","journal-title":"Clin. Cancer Res."},{"key":"300_CR124","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-induced JAK\/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2019).","journal-title":"Cancer Discov."},{"key":"300_CR125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","volume":"569","author":"Y Shi","year":"2018","unstructured":"Shi, Y. et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature 569, 131\u2013135 (2018).","journal-title":"Nature"},{"key":"300_CR126","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910515","volume":"11","author":"H Huang","year":"2019","unstructured":"Huang, H. et al. Targeting TGFbetaR2-mutant tumors exposes vulnerabilities to stromal TGFbeta blockade in pancreatic cancer. EMBO Mol. Med. 11, e10515 (2019).","journal-title":"EMBO Mol. Med."},{"key":"300_CR127","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"300_CR128","volume":"5","author":"AN Hosein","year":"2019","unstructured":"Hosein, A. N. et al. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight 5, e129212 (2019).","journal-title":"JCI Insight"},{"key":"300_CR129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","volume":"76","author":"MJ Barnden","year":"1998","unstructured":"Barnden, M. J. et al. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34\u201340 (1998).","journal-title":"Immunol. Cell Biol."},{"key":"300_CR130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2019","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2019).","journal-title":"Cancer Discov."},{"key":"300_CR131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"178","author":"M Ligorio","year":"2019","unstructured":"Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160\u2013175 (2019).","journal-title":"Cell"},{"key":"300_CR132","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","volume":"17","author":"N Erez","year":"2010","unstructured":"Erez, N. et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17, 135\u2013147 (2010).","journal-title":"Cancer Cell"},{"key":"300_CR133","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q., Lenardo, M. J. & Baltimore, D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell 168, 37\u201357 (2017).","journal-title":"Cell"},{"key":"300_CR134","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2018","unstructured":"Biffi, G. et al. IL-1-induced JAK\/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2018).","journal-title":"Cancer Discov."},{"key":"300_CR135","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","volume":"78","author":"D Zhang","year":"2018","unstructured":"Zhang, D. et al. Tumor-stroma IL1beta-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 78, 1700\u20131712 (2018).","journal-title":"Cancer Res."},{"key":"300_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02021422 (2017)."},{"key":"300_CR137","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10637-018-0580-2","volume":"36","author":"H Hurwitz","year":"2018","unstructured":"Hurwitz, H. et al. Ruxolitinib + capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest. N. Drugs 36, 683\u2013695 (2018).","journal-title":"Invest. N. Drugs"},{"key":"300_CR138","doi-asserted-by":"crossref","first-page":"E1147","DOI":"10.1073\/pnas.1717802115","volume":"115","author":"M Djurec","year":"2018","unstructured":"Djurec, M. et al. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc. Natl Acad. Sci. USA 115, E1147\u2013E1156 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03086369 (2020)."},{"key":"300_CR140","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR141","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.gastro.2018.05.051","volume":"155","author":"B Garg","year":"2018","unstructured":"Garg, B. et al. NFkappaB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12. Gastroenterology 155, 880\u2013891 (2018).","journal-title":"Gastroenterology"},{"key":"300_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03168139 (2019)."},{"key":"300_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02826486 (2020)."},{"issue":"Suppl. 11","key":"300_CR144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/annonc\/mdz451","volume":"30","author":"M Hidalgo","year":"2019","unstructured":"Hidalgo, M. et al. A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). Ann. Oncol. 30 (Suppl. 11) 33 (2019).","journal-title":"Ann. Oncol."},{"key":"300_CR145","doi-asserted-by":"crossref","first-page":"65982","DOI":"10.18632\/oncotarget.11786","volume":"7","author":"NS Nagathihalli","year":"2016","unstructured":"Nagathihalli, N. S. et al. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget 7, 65982\u201365992 (2016).","journal-title":"Oncotarget"},{"key":"300_CR146","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1535-7163.MCT-16-0899","volume":"16","author":"KB Long","year":"2017","unstructured":"Long, K. B. et al. IL6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 16, 1898\u20131908 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"300_CR147","volume":"96","author":"HW Kim","year":"2017","unstructured":"Kim, H. W. et al. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine 96, e5926 (2017).","journal-title":"Medicine"},{"key":"300_CR148","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249\u2013252 (2019).","journal-title":"Nature"},{"key":"300_CR149","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/d41586-019-00710-z","volume":"567","author":"A Maitra","year":"2019","unstructured":"Maitra, A. Molecular envoys pave the way for pancreatic cancer to invade the liver. Nature 567, 181\u2013182 (2019).","journal-title":"Nature"},{"key":"300_CR150","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02767557 (2019)."},{"key":"300_CR151","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ijc.29445","volume":"137","author":"FA Goumas","year":"2015","unstructured":"Goumas, F. A. et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137, 1035\u20131046 (2015).","journal-title":"Int. J. Cancer"},{"key":"300_CR152","doi-asserted-by":"crossref","first-page":"1000234","DOI":"10.4172\/2168-9784.1000234","volume":"6","author":"S Mitsunaga","year":"2017","unstructured":"Mitsunaga, S. et al. Multicenter, open-label, phase I\/II study of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, combined with gemcitabine in patients with advanced pancreatic cancer. J. Med. Diagn. Methods 6, 1000234 (2017).","journal-title":"J. Med. Diagn. Methods"},{"key":"300_CR153","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","volume":"24","author":"TR Flint","year":"2016","unstructured":"Flint, T. R. et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24, 672\u2013684 (2016).","journal-title":"Cell Metab."},{"key":"300_CR154","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320\u2013332 (2018).","journal-title":"Gut"},{"key":"300_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04191421 (2020)."},{"key":"300_CR156","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"121","author":"A Orimo","year":"2005","unstructured":"Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell 121, 335\u2013348 (2005).","journal-title":"Cell"},{"key":"300_CR157","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","volume":"14","author":"JM Bailey","year":"2008","unstructured":"Bailey, J. M. et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995\u20136004 (2008).","journal-title":"Clin. Cancer Res."},{"key":"300_CR158","doi-asserted-by":"crossref","first-page":"E3091","DOI":"10.1073\/pnas.1411679111","volume":"111","author":"JJ Lee","year":"2014","unstructured":"Lee, J. J. et al. Stromal response to hedgehog signaling restrains pancreatic cancer progression. Proc. Natl Acad. Sci. USA 111, E3091\u2013E3100 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"300_CR159","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","volume":"33","author":"DV Catenacci","year":"2015","unstructured":"Catenacci, D. V. et al. Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J. Clin. Oncol. 33, 4284\u20134292 (2015).","journal-title":"J. Clin. Oncol."},{"key":"300_CR160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","volume":"45","author":"AH Ko","year":"2016","unstructured":"Ko, A. H. et al. A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas 45, 370\u2013375 (2016).","journal-title":"Pancreas"},{"key":"300_CR161","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.495","volume":"111","author":"M Sinn","year":"2014","unstructured":"Sinn, M. et al. \u03b1-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br. J. Cancer 111, 1917\u20131923 (2014).","journal-title":"Br. J. Cancer"},{"key":"300_CR162","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257\u2013272 (2011).","journal-title":"Cancer Cell"},{"key":"300_CR163","doi-asserted-by":"crossref","first-page":"8492","DOI":"10.1158\/0008-5472.CAN-04-1708","volume":"64","author":"NC Direkze","year":"2004","unstructured":"Direkze, N. C. et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64, 8492\u20138495 (2004).","journal-title":"Cancer Res."},{"key":"300_CR164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004992","volume":"4","author":"EL Spaeth","year":"2009","unstructured":"Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4, e4992 (2009).","journal-title":"PLoS One"},{"key":"300_CR165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","volume":"449","author":"AE Karnoub","year":"2007","unstructured":"Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557\u2013563 (2007).","journal-title":"Nature"},{"key":"300_CR166","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/2159-8290.CD-15-0947","volume":"6","author":"M Waghray","year":"2016","unstructured":"Waghray, M. et al. GM-CSF mediates mesenchymal-epithelial cross-talk in pancreatic cancer. Cancer Discov. 6, 886\u2013899 (2016).","journal-title":"Cancer Discov."},{"key":"300_CR167","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne, L. J. et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822\u2013835 (2012).","journal-title":"Cancer Cell"},{"key":"300_CR168","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta, Y. et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836\u2013847 (2012).","journal-title":"Cancer Cell"},{"key":"300_CR169","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/0008-5472.CAN-14-2921","volume":"75","author":"S Takeuchi","year":"2015","unstructured":"Takeuchi, S. et al. Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res. 75, 2629\u20132640 (2015).","journal-title":"Cancer Res."},{"key":"300_CR170","doi-asserted-by":"publisher","DOI":"10.13140\/RG.2.2.28962.53443","author":"ZA Wainberg","year":"2019","unstructured":"Wainberg, Z. A. et al. First-in-human phase 1 dose escalation and expansion of a novel combination, anti-CSF-1 receptor (cabiralizumab) plus anti-PD-1 (nivolumab), in patients with advanced solid tumors. Society for Immunotherapy of Cancer https:\/\/doi.org\/10.13140\/RG.2.2.28962.53443 (2019).","journal-title":"Society for Immunotherapy of Cancer"},{"key":"300_CR171","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2016.03.029","volume":"165","author":"CJ Tape","year":"2016","unstructured":"Tape, C. J. et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165, 910\u2013992 (2016).","journal-title":"Cell"},{"key":"300_CR172","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/0008-5472.CAN-17-1973","volume":"78","author":"KF Ludwig","year":"2018","unstructured":"Ludwig, K. F. et al. Small-molecule inhibition of AXL targets tumor immune suppression and enhances chemotherapy in pancreatic cancer. Cancer Res. 78, 246\u2013255 (2018).","journal-title":"Cancer Res."},{"key":"300_CR173","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","volume":"76","author":"L Ireland","year":"2016","unstructured":"Ireland, L. et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 76, 6851\u20136863 (2016).","journal-title":"Cancer Res."},{"key":"300_CR174","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/0008-5472.CAN-16-1383","volume":"77","author":"AA Rucki","year":"2017","unstructured":"Rucki, A. A. et al. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. 77, 41\u201352 (2017).","journal-title":"Cancer Res."},{"key":"300_CR175","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","volume":"26","author":"CS Fuchs","year":"2015","unstructured":"Fuchs, C. S. et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann. Oncol. 26, 921\u2013927 (2015).","journal-title":"Ann. Oncol."},{"key":"300_CR176","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annonc.2019.09.004","volume":"31","author":"M Kundranda","year":"2020","unstructured":"Kundranda, M. et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann. Oncol. 31, 79\u201387 (2020).","journal-title":"Ann. Oncol."},{"key":"300_CR177","doi-asserted-by":"crossref","first-page":"14303","DOI":"10.1016\/S0021-9258(17)36789-3","volume":"269","author":"KL Carraway 3rd","year":"1994","unstructured":"Carraway, K. L. 3rd et al. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 269, 14303\u201314306 (1994).","journal-title":"J. Biol. Chem."},{"key":"300_CR178","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.28744","volume":"120","author":"PA Philip","year":"2014","unstructured":"Philip, P. A. et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer 120, 2980\u20132985 (2014).","journal-title":"Cancer"},{"key":"300_CR179","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-018-0616-2","volume":"11","author":"R Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, R. et al. Randomized, phase I\/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J. Hematol. Oncol. 11, 71 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"300_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02729298 (2019)."},{"key":"300_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03649321 (2020)."},{"key":"300_CR182","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"159","author":"MH Sherman","year":"2014","unstructured":"Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80\u201393 (2014).","journal-title":"Cell"},{"key":"300_CR183","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/gutjnl-2018-316627","volume":"68","author":"F Kong","year":"2019","unstructured":"Kong, F. et al. VDR signaling inhibits cancer-associated-fibroblasts\u2019 release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. Gut 68, 950\u2013951 (2019).","journal-title":"Gut"},{"key":"300_CR184","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1053\/j.gastro.2009.08.065","volume":"137","author":"FU Weiss","year":"2009","unstructured":"Weiss, F. U. et al. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 137, 2136\u20132145.e1\u20137 (2009).","journal-title":"Gastroenterology"},{"key":"300_CR185","doi-asserted-by":"crossref","first-page":"dju185","DOI":"10.1093\/jnci\/dju185","volume":"106","author":"K Van Loon","year":"2014","unstructured":"Van Loon, K., et al. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J. Natl Cancer Inst. 106, dju185 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"300_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03472833 (2019)."},{"key":"300_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03300921 (2020)."},{"issue":"Suppl. 4","key":"300_CR188","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2018.36.4_suppl.358","volume":"36","author":"EH Borazanci","year":"2018","unstructured":"Borazanci, E. H. et al. A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 36 (Suppl. 4), 358 (2018).","journal-title":"J. Clin. Oncol."},{"key":"300_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02754726 (2020)."},{"key":"300_CR190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111\u2013121 (2013).","journal-title":"N. Engl. J. Med."},{"key":"300_CR191","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12630","volume":"7","author":"A Chronopoulos","year":"2016","unstructured":"Chronopoulos, A. et al. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat. Commun. 7, 12630 (2016).","journal-title":"Nat. Commun."},{"key":"300_CR192","doi-asserted-by":"crossref","DOI":"10.1038\/srep27639","volume":"6","author":"M Sarper","year":"2016","unstructured":"Sarper, M. et al. ATRA modulates mechanical activation of TGF-beta by pancreatic stellate cells. Sci. Rep. 6, 27639 (2016).","journal-title":"Sci. Rep."},{"key":"300_CR193","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1053\/j.gastro.2011.06.047","volume":"141","author":"FE Froeling","year":"2011","unstructured":"Froeling, F. E. et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 141, 1486\u20131497 e1\u201314 (2011).","journal-title":"Gastroenterology"},{"key":"300_CR194","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4727","volume":"239","author":"EF Carapuca","year":"2016","unstructured":"Carapuca, E. F. et al. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J. Pathol. 239, 286\u2013296 (2016).","journal-title":"J. Pathol."},{"issue":"Suppl. 5","key":"300_CR195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdz247.027","volume":"30","author":"HM Kocher","year":"2019","unstructured":"Kocher, H. M. et al. 700P - STAR-PAC: phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. Ann. Oncol. 30 (Suppl. 5), 267 (2019).","journal-title":"Ann. Oncol."},{"key":"300_CR196","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1200\/EDBK_159117","volume":"35","author":"LM Matrisian","year":"2016","unstructured":"Matrisian, L. M. & Berlin, J. D. The past, present, and future of pancreatic cancer clinical trials. Am. Soc. Clin. Oncol. Educ. Book 35, e205\u2013e215 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"300_CR197","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/MPA.0b013e318296f866","volume":"42","author":"Y Akashi","year":"2013","unstructured":"Akashi, Y. et al. Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. Pancreas 42, 1275\u20131282 (2013).","journal-title":"Pancreas"},{"key":"300_CR198","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"300_CR199","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"22","author":"T Seino","year":"2018","unstructured":"Seino, T. et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell 22, 454\u2013467 (2018).","journal-title":"Cell Stem Cell"},{"key":"300_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03307148 (2020)."},{"key":"300_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02399137 (2018)."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-0300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-0300-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-0300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:52:49Z","timestamp":1684605169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-0300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":201,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1038\/s41575-020-0300-1","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"24 March 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. receives royalties from Cosmos Wisdom Biotechnology for a biomarker assay related to early detection of pancreatic cancer. A.M. is an inventor on a patent that has been licensed to Thrive Earlier Detection. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}